Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Mortality Reduction by year

Principal Investigator
Name
Rowena Yip
Degrees
PhD, MPH
Institution
Icahn School of Medicine at Mount Sinai
Position Title
Biostatistician
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-16
Initial CDAS Request Approval
Apr 17, 2013
Title
Mortality Reduction by year
Summary
We are interested in determining the rate of lung cancer deaths prevented by screening on an annual basis. The PLCO data is ideal for this due to its large size and long period of follow up. In this way we will see when the effect of screening becomes maximal as well as when the effect is no longer apparent. In order to make these determinations we will need to know when the screening occurred, and when the cancer was diagnosed, and also whether the cancer was diagnosed as a result of screening or was either interval or was diagnosed after screening was completed. We will also need to know whether the patient was alive or died of the cancer and any other information if available regarding competing cause of death or recurrent disease. We will also need to be able to compare this information with the control arm of the study.
Aims

1- Determine proportional reduction in mortality as a function of time
2- Determine when effects related to the screening reach their maximum
3- Determine when effects from screening are no longer apparent
4- Determine rates of competing caused of death

Collaborators

1) David Yankelevitz, Tisch Cancer Center, Mount Sinai School of Medicine
2) Claudia Henschke, Tisch Cancer Center, Mount Sinai School of Medicine
3) Paolo Boffetta, Institute for Translational Epidemiology, Mount Sinai School of Medicine

Related Publications